-
公开(公告)号：US09458447B2
公开(公告)日：2016-10-04
申请号：US14131019
申请日：2012-08-09
IPC分类号： C07K7/00 , A61K38/10 , C12N9/00 , A61K39/00 , C07K14/47 , C12N9/14 , G01N33/50 , C12N5/0784 , C12N5/10 , G01N33/574 , A61K38/00
CPC分类号： C12N9/93 , A61K38/00 , A61K39/00 , A61K39/0011 , C07K14/4738 , C12N5/0639 , C12N5/10 , C12N9/14 , C12N2502/1114 , C12Y306/04004 , G01N33/505 , G01N33/57407 , G01N2440/14
摘要： As discussed in greater detail herein, isolated epitope peptides derived from MPHOSPH1 bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned MPHOSPH1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical agents or compositions of this invention find particular utility in either or both of the treatment and prevention of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal cancer and soft tissue tumor.
摘要翻译： 如本文更详细讨论的，衍生自MPHOSPH1的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL），因此适用于癌症免疫治疗，特别是癌症疫苗的上下文中。 本发明的肽包括上述提供的MPHOSPH1衍生的氨基酸序列及其修饰形式，其中一个，两个或几个氨基酸被取代，缺失，插入或添加，只要这些修饰形式保持必需的CTL诱导性 原始序列。 还提供了编码任何前述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物或组合物。 本发明的肽，多核苷酸和药物或组合物在癌症和肿瘤的治疗和预防中的任一个或两者中都具有特别的用途，包括例如膀胱癌，乳腺癌，宫颈癌，胆管细胞癌，CML，结肠直肠 癌症，胃癌，NSCLC，淋巴瘤，骨肉瘤，前列腺癌，肾癌和软组织肿瘤。
-
公开(公告)号：US09056890B2
公开(公告)日：2015-06-16
申请号：US13880442
申请日：2011-10-20
CPC分类号： C07K7/06 , A61K38/00 , A61K39/0011 , C07K14/47
摘要： Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides or immunogenic fragments derived from SEQ ID NO: 32, that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) are provided. The amino acid sequence of the peptide of interest may be optionally modified with the substitution, deletion, insertion, or addition of one, two, or several amino acids sequences. Pharmaceutical compositions and methods of treating cancer that include such peptides are also provided.
摘要翻译： 本文描述了针对癌症的肽疫苗。 特别地，提供了与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的衍生自SEQ ID NO：32的分离的表位肽或免疫原性片段。 感兴趣的肽的氨基酸序列可以任选地用一个，两个或几个氨基酸序列的取代，缺失，插入或添加来修饰。 还提供了包括这些肽的药物组合物和治疗癌症的方法。
-
公开(公告)号：US20140023671A1
公开(公告)日：2014-01-23
申请号：US13990766
申请日：2011-11-25
申请人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe , Gaku Nakayama
发明人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe , Gaku Nakayama
CPC分类号： C07K7/06 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , C07K14/705 , C12N5/0638 , C12N2501/998 , C12N2502/1114 , C12N2502/1121 , G01N33/57407
摘要： The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 42, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.
摘要翻译： 本发明提供分离的肽或衍生自SEQ ID NO：42的片段，其结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL）。 肽可以包括一个上述氨基酸序列中的一个，两个或几个氨基酸序列的取代，缺失或添加。 本发明还提供包含这些肽的药物组合物。 本发明的肽可用于治疗癌症。
-
公开(公告)号：US09187556B2
公开(公告)日：2015-11-17
申请号：US14118693
申请日：2012-06-07
申请人： Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe , Gaku Nakayama , Yusuke Nakamura
发明人： Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe , Gaku Nakayama , Yusuke Nakamura
CPC分类号： C07K16/18 , A61K38/00 , A61K39/0011 , C07K14/4703 , G01N33/57492 , G01N2333/70539
摘要： As discussed in detail herein, isolated epitope peptides derived from SEMA5B bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, pharmaceutical agents or compositions of this invention find particular utility in the treatment and/or prevention of cancers and tumors, including, for example, esophageal cancer, NSCLC, RCC and SCLC.
摘要翻译： 如本文详细讨论的，衍生自SEMA5B的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL），因此适合用于癌症免疫治疗，尤其是癌症疫苗的上下文中。 本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或若干个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保持必需的HLA结合和/或CTL诱导性 原始序列。 还提供了编码任何上述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物试剂或组合物。 本发明的肽，多核苷酸，药物或组合物特别用于治疗和/或预防癌症和肿瘤，包括例如食管癌，NSCLC，RCC和SCLC。
-
公开(公告)号：US20140178409A1
公开(公告)日：2014-06-26
申请号：US14118693
申请日：2012-06-07
申请人： Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe , Gaku Nakayama , Yusuke Nakamura
发明人： Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe , Gaku Nakayama , Yusuke Nakamura
IPC分类号： C07K16/18
CPC分类号： C07K16/18 , A61K38/00 , A61K39/0011 , C07K14/4703 , G01N33/57492 , G01N2333/70539
摘要： As discussed in detail herein, isolated epitope peptides derived from SEMA5B bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, pharmaceutical agents or compositions of this invention find particular utility in the treatment and/or prevention of cancers and tumors, including, for example, esophageal cancer, NSCLC, RCC and SCLC.
摘要翻译： 如本文详细讨论的，衍生自SEMA5B的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL），因此适合用于癌症免疫治疗，尤其是癌症疫苗的上下文中。 本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或若干个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保持必需的HLA结合和/或CTL诱导性 原始序列。 还提供了编码任何上述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物试剂或组合物。 本发明的肽，多核苷酸，药物或组合物特别用于治疗和/或预防癌症和肿瘤，包括例如食管癌，NSCLC，RCC和SCLC。
-
公开(公告)号：US20130309259A1
公开(公告)日：2013-11-21
申请号：US13880442
申请日：2011-10-20
IPC分类号： C07K7/06
CPC分类号： C07K7/06 , A61K38/00 , A61K39/0011 , C07K14/47
摘要： Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides or immunogenic fragments derived from SEQ ID NO: 32, that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) are provided. The amino acid sequence of the peptide of interest may be optionally modified with the substitution, deletion, insertion, or addition of one, two, or several amino acids sequences. Pharmaceutical compositions and methods of treating cancer that include such peptides are also provided.
摘要翻译： 本文描述了针对癌症的肽疫苗。 特别地，提供了与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的衍生自SEQ ID NO：32的分离的表位肽或免疫原性片段。 感兴趣的肽的氨基酸序列可以任选地用一个，两个或几个氨基酸序列的取代，缺失，插入或添加来修饰。 还提供了包括这些肽的药物组合物和治疗癌症的方法。
-
公开(公告)号：US20130287805A1
公开(公告)日：2013-10-31
申请号：US13880632
申请日：2011-10-19
IPC分类号： A61K39/00
CPC分类号： A61K39/0011 , A61K38/00 , C07K14/47
摘要： Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides or immunogenic fragments derived from SEQ ID NO: 35, that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) are provided. The amino acid sequences of the peptide of interest may be optionally modified with the substitution, deletion, insertion, or addition of one, two, or several amino acids sequences. Pharmaceutical compositions and methods of treating cancer that include such peptides are also provided.
摘要翻译： 本文描述了针对癌症的肽疫苗。 特别地，提供了与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的衍生自SEQ ID NO：35的分离的表位肽或免疫原性片段。 感兴趣的肽的氨基酸序列可以任选地用一个，两个或几个氨基酸序列的取代，缺失，插入或添加来修饰。 还提供了包括这些肽的药物组合物和治疗癌症的方法。
-
公开(公告)号：US09125849B2
公开(公告)日：2015-09-08
申请号：US13990766
申请日：2011-11-25
申请人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe , Gaku Nakayama
发明人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe , Gaku Nakayama
IPC分类号： C07K14/00 , A61K39/00 , C07K14/705 , G01N33/574 , C07K7/06 , A61K38/00
CPC分类号： C07K7/06 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , C07K14/705 , C12N5/0638 , C12N2501/998 , C12N2502/1114 , C12N2502/1121 , G01N33/57407
摘要： The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 42, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.
摘要翻译： 本发明提供分离的肽或衍生自SEQ ID NO：42的片段，其结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL）。 肽可以包括一个上述氨基酸序列中的一个，两个或几个氨基酸序列的取代，缺失或添加。 本发明还提供包含这些肽的药物组合物。 本发明的肽可用于治疗癌症。
-
公开(公告)号：US20140154281A1
公开(公告)日：2014-06-05
申请号：US14131019
申请日：2012-08-09
CPC分类号： C12N9/93 , A61K38/00 , A61K39/00 , A61K39/0011 , C07K14/4738 , C12N5/0639 , C12N5/10 , C12N9/14 , C12N2502/1114 , C12Y306/04004 , G01N33/505 , G01N33/57407 , G01N2440/14
摘要： As discussed in greater detail herein, isolated epitope peptides derived from MPHOSPH1 bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned MPHOSPH1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical agents or compositions of this invention find particular utility in either or both of the treatment and prevention of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal cancer and soft tissue tumor.
摘要翻译： 如本文更详细讨论的，衍生自MPHOSPH1的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL），因此适用于癌症免疫治疗，特别是癌症疫苗的上下文中。 本发明的肽包括上述提供的MPHOSPH1衍生的氨基酸序列及其修饰形式，其中一个，两个或几个氨基酸被取代，缺失，插入或添加，只要这些修饰形式保持必需的CTL诱导性 原始序列。 还提供了编码任何前述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物或组合物。 本发明的肽，多核苷酸和药物或组合物在癌症和肿瘤的治疗和预防中的任一个或两者中都具有特别的用途，包括例如膀胱癌，乳腺癌，宫颈癌，胆管细胞癌，CML，结肠直肠 癌症，胃癌，NSCLC，淋巴瘤，骨肉瘤，前列腺癌，肾癌和软组织肿瘤。
-
公开(公告)号：US08697631B2
公开(公告)日：2014-04-15
申请号：US13515656
申请日：2010-12-13
CPC分类号： C07K7/06 , A61K39/00 , A61K39/0011 , A61K2039/57 , C07K14/705
摘要： Isolated peptides composed of the amino acid sequence of SEQ ID NO: 33 or fragments thereof that bind to HLA antigens and have cytotoxic T lymphocyte (CTL) inducibility and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical agents, substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors.
摘要翻译： 描述了由SEQ ID NO：33的氨基酸序列组成的分离肽或其与HLA抗原结合并具有细胞毒性T淋巴细胞（CTL）诱导性的因此适合用于癌症免疫治疗，特别是癌症疫苗的上下文中的其片段 这里。 本发明进一步提供了肽，其包括前述肽或片段的一个，两个或几个氨基酸插入，取代或添加，但仍保留所需的细胞毒性T细胞诱导性。 还提供了编码任何上述肽的核酸以及包含上述肽或核酸中任何一种的药物，物质和组合物。 本发明的肽，核酸，药物，物质和组合物在癌症和肿瘤的治疗中具有特别的用途。
-
-
-
-
-
-
-
-
-
搜索结果
338 条记录 (耗时 0.034 秒)
